Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
105.9 USD | -0.04% | -1.55% | -3.83% |
Apr. 29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
Apr. 26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.83% | 184B | |
-0.95% | 107B | |
-3.53% | 69.44B | |
+3.55% | 50.37B | |
+8.63% | 44.82B | |
+3.40% | 41.53B | |
+3.11% | 26.84B | |
+3.85% | 26.73B | |
+15.23% | 25.71B | |
-0.53% | 24.34B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Transcript : Abbott Laboratories, Q1 2024 Earnings Call, Apr 17, 2024